BioNTech SE

BNTX12 Dec 2024
Healthcare
$119.49
+0.02 (+2.02%)
Lowest Today
$118.68
Highest Today
$121.68
Today’s Open
$119.49
Prev. Close
$116.85
52 Week High
$131.49
52 Week Low
$76.53
To Invest in BioNTech SE

BioNTech SE

Healthcare
BNTX12 Dec 2024
+0.02 (+2.02%)
1M
3M
6M
1Y
5Y
Low
$118.68
Day’s Range
High
$121.68
118.68
52 Week Low
$76.53
52-Week Range
52 Week High
$131.49
76.53
1 Day
-
1 Week
+2%
1 month return
+7.63%
3 month return
+17.67%
6 month return
+18.53%
1 Year return
+16.42%
3 Years return
-57.32%
5 Years return
+279.77%
10 Years return
-
Institutional Holdings
Baillie Gifford & Co Limited.
3.47
FMR Inc
2.63
PRIMECAP Management Company
1.88
Flossbach von Storch AG
1.82
FvS SICAV Multiple Opportunities F
1.19
Vanguard Capital Opportunity Inv
0.95
BlackRock Inc
0.79

Market Status

Fundamentals
Market Cap
28965.39 mln
PB Ratio
1.44
PE Ratio
0
Enterprise Value
11751.78 mln
Total Assets
23006.3 mln
Volume

Company Financials

Fund house & investment objective

Company Information
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac
Organisation
BioNTech SE
Employees
6133
Industry
Biotechnology
CEO
Dr. Ugur  Sahin M.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step